AWAKE LM TT
Alternative Names: Awake 101; Awake 102; Awake 103; AWAKE-LM-TT; Listeria tetanus toxoid; Listeria TT; Lm LLO TTLatest Information Update: 01 Jul 2026
At a glance
- Originator Loki Therapeutics
- Developer Loki Therapeutics; Matter Bio
- Class Antineoplastics; Bacterial antigens; Bacterial toxins; Immunotherapies
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Adenocarcinoma; Glioblastoma; Ovarian cancer
- Research Breast cancer; Colorectal cancer; Liver cancer; Lung cancer
Most Recent Events
- 01 Jul 2026 AWAKE LM TT is still in preclinical phase for Ovarian cancer in USA (Loki therapeutics pipeline, July 2026)
- 01 Jul 2026 Preclinical trials in Glioblastoma in USA (Parenteral) prior to July 2026 (Matter Bio pipeline, July 2026)
- 10 Jun 2026 US FDA approves IND application for LM LLO TT in Adenocarcinoma